Patient Profile 1: A Patient With HER2+ Metastatic BC Treated With T-DXd who Develops ILD

Kristine Gibbons, RN, OCN, who is a Nurse Trainer at Florida Cancer Specialists & Research Institute, provides an in-depth look at elacestrant in a downloadable fact sheet.

In this episode of "The Vitals," Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, underscores potentially practice-changing data which were presented during the 2023 GI Cancers Symposium.

For patients with ER-positive breast cancer who remain premenopausal—or regain ovarian function—following chemotherapy, 2 years of ovarian suppression may be beneficial.

Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.

Lorazepam was associated with worse survival outcomes for patients with pancreatic cancer, while alprazolam was associated with improved outcomes.

Stronger interventions are needed to improve adjuvant treatment rates among breast cancer survivors.